FTC Sues Hims & Hers Over Selling Patient Data to Advertisers

The Federal Trade Commission (FTC) has filed a lawsuit accusing Hims & Hers of selling patients' sensitive health data to major advertisers.

Core Allegations

■Hims & Hers allegedly embedded pixel trackers from Meta, Snap, Microsoft, Pinterest, Reddit, and X, capturing users' health information.

■The trackers recorded clickstreams, page navigation, and prescription histories, funneling personal health data to third‑party advertisers.

■The FTC claims the company violated its own privacy policy and engaged in deceptive billing practices.

Surveillance and Tech‑Tracking Mechanics

■Pixel‑sized trackers supplied by Meta and Snap were embedded on Hims & Hers’ website, enabling real‑time data flow.

■These trackers allowed ad platforms to build detailed user profiles and run highly targeted campaigns.

■According to the FTC, the trackers harvested health‑related data (e.g., sexual wellness, mental health, weight‑loss treatments) in breach of disclosed privacy terms.

Financial Implications and Stock Risk

■Hims & Hers trades under NASDAQ: HIMS; it reported $1.1 bn revenue for fiscal 2023.

■Regulatory uncertainty introduces a short‑term 8%‑12% equity downside risk.

■Potential fines and settlements could strain the company's $200 mn liquidity cushion.

■Investors are likely to shift toward risk‑off positioning pending the lawsuit’s outcome.

Precedent Regulatory Actions

■The FTC has previously targeted Cerebral, Monument, GoodRx, and BetterHelp for similar data‑sharing violations.

■Those cases established a sector‑wide framework for data‑privacy compliance in tele‑health.

■Historical outcomes showed an average 15% market‑value erosion and heightened stock volatility.

The FTC’s aggressive stance signals heightened scrutiny for digital health firms and could reshape industry data‑privacy norms. Liquidity management and legal‑risk pricing are expected to feed into valuation models, especially in a risk‑on environment. While short‑term selling pressure is probable, the longer‑term cost of compliance and its impact on profitability merit close monitoring.